June 9, 2026
CatalYm Appoints Peter Garcia as Chief Financial Officer
CatalYm Appoints Peter Garcia as Chief Financial Officer Munich, Germany and...
Read More
April 28, 2026
CatalYm Appoints Christian S. Schade as Chairman of the Board of Directors
CatalYm Appoints Christian S. Schade as Chairman of the Board of Directors...
Read More
April 23, 2026
CatalYm Advances Visugromab into Phase 2/3 Development for Cancer Cachexia with First Patient Dosed
CatalYm Advances Visugromab into Phase 2/3 Development for Cancer Cachexia with First...
Read More
April 7, 2026
CatalYm Doses First Patient in Phase 2b Trial Evaluating Visugromab in Combination with Chemoimmunotherapy as Second-Line Treatment in Unresectable/Metastatic Hepatocellular Carcinoma
CatalYm Doses First Patient in Phase 2b Trial Evaluating Visugromab in Combination...
Read More
March 10, 2026
IASLC 2026 World Conference on Lung Cancer
September 12 – September 15, 2026
Seoul, South Korea
December 2, 2025
CatalYm Announces First Patient Dosed in Phase 2b Trial Evaluating Visugromab in Combination with Chemoimmunotherapy as Second-Line Treatment in Metastatic Non-squamous NSCLC
CatalYm Announces First Patient Dosed in Phase 2b Trial Evaluating Visugromab in...
Read More
November 7, 2025
GDFATHER-01 Trial Long Term Follow-Up: GDF-15 Neutralization Combined With Nivolumab Can Enable Deep, Long-Term Remission In Heavily Pretreated, Anti-PD1/-L1 Relapsed/ Refractory Major Solid Tumor Types
Ignacio Melero Bermejo, María de Miguel Luken, Elena Garralda Cabanas, Guillermo de...
Read More
October 20, 2025
CatalYm Presents Long-Term Phase 1/2a Data Confirming Sustained Responses with Visugromab in CPI-Refractory Tumors at ESMO 2025
CatalYm Presents Long-Term Phase 1/2a Data Confirming Sustained Responses with Visugromab in...
Read More